IFITM1 and neoplasm: Together, these findings suggest that both IFIT1 and IFITM1 contribute to therapy resistance and tumor progression, likely through modulation of interferon and growth factor signaling pathways and may represent potential targets for therapeutic intervention in cancers characterized by high PARP13 and ISG expression.